Myricetin attenuates LPS-induced inflammation in RAW 264.7 macrophages and mouse models

Acute lung injury is a common clinical syndrome associated with significant morbidity. Myricetin has been demonstrated to inhibit inflammation in a variety of diseases. In this study, we aimed to investigate the protective effects of myricetin on inflammation in lipopolysaccharide-stimulated RAW 264...

Full description

Saved in:
Bibliographic Details
Published in:Future medicinal chemistry 2018-10, Vol.10 (19), p.2253-2264
Main Authors: Hou, Wei, Hu, Siyi, Su, Zhenzhong, Wang, Qi, Meng, Guangping, Guo, Tingting, Zhang, Jie, Gao, Peng
Format: Article
Language:English
Subjects:
acute lung injury
inflammatory diseases
lipopolysaccharide
macrophage
myricetin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute lung injury is a common clinical syndrome associated with significant morbidity. Myricetin has been demonstrated to inhibit inflammation in a variety of diseases. In this study, we aimed to investigate the protective effects of myricetin on inflammation in lipopolysaccharide-stimulated RAW 264.7 cells and lipopolysaccharide-induced lung injury model. In this study, we detected the anti-inflammatory effects of myricetin by ELISA, RT-PCR and Western blot, respectively. Myricetin significantly inhibited the production of the proinflammatory cytokines and . It exerted an anti-inflammatory effect through suppressing the NF-κB p65 and AKT activation in NF-κB pathway and JNK, p-ERK and p38 in MAPK signaling pathway. Myricetin alleviated acute lung injury by inhibiting macrophage activation, and inhibited inflammation and . It may be a potential therapeutic candidate for the prevention of inflammatory diseases.
ISSN:1756-8919
1756-8927
DOI:10.4155/fmc-2018-0172